SCHEMBL15045666

SCHEMBL15045666

CC(=O)C(Nc1ncccn1)C1CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
ALOX12 P18054 1/20 0.34
NCOA1 Q15788 1/20 0.34
NCOA3 Q9Y6Q9 1/20 0.34
KDM4E B2RXH2 1/20 0.34
GAA P10253 1/20 0.34
ACACB O00763 2/20 0.33
EPHX2 P34913 1/20 0.33
NPR3 P17342 1/20 0.33
MAPK1 P28482 1/20 0.33
IDH1 O75874 3/20 0.32
FFAR2 O15552 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19486074 0.83 ALDH1A1 (0.40) ALDH1A1NPSR1LMNAHTTNPC1
SCHEMBL12076597 0.76 ALDH1A1 (0.49) ALDH1A1NPSR1RAB9AKDM4EGAA
SCHEMBL12966146 0.73 LMNA (0.43) ALDH1A1NPSR1LMNAHTTL3MBTL1
SCHEMBL13127917 0.72 HTT (0.46) ALDH1A1NPSR1LMNAHTTL3MBTL1
SCHEMBL10299129 0.68 LMNA (0.42) ALDH1A1LMNAHTTL3MBTL1NPC1
SCHEMBL26799508 0.68 ALDH1A1 (0.44) ALDH1A1NPSR1KDM4EGAANPR3
SCHEMBL10206346 0.66
SCHEMBL14942950 0.66
SCHEMBL7513825 0.66 KDM4E (0.50) ALDH1A1NPSR1HTTKDM4EGAA
SCHEMBL12965975 0.65 PREP (0.32) ALDH1A1KDM4EEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796705-B2 Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases MERCK SHARP & DOHME CORP. (US) 2017-10-24 US disclosed
US-20170008879-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2017-01-12 US disclosed
US-20130156731-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS SCHERING CORPORATION 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130156731-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS HAVCR2, ELOC, ZC3HAV1 ALDH1A1 578/4885NPSR1 2897/4885LMNA 1245/4885
US-20170008879-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES ZC3HAV1, HAVCR2, ZC3HAV1L ALDH1A1 3470/4885NPSR1 4039/4885LMNA 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.